Literature DB >> 29066521

Bone protective agents in children.

Claire Louise Wood1,2, S Faisal Ahmed3.   

Abstract

Evaluation of bone health in childhood is important to identify children who have inadequate bone mineralisation and who may benefit from interventions to decrease their risk of osteoporosis and subsequent fracture. There are no bone protective agents that are licensed specifically for the prevention and treatment of osteoporosis in children. In this review, we discuss the mechanism of action and use of bisphosphonates and other new and established bone protective agents in children. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  bone disease; therapeutics

Mesh：

Substances：

Year:  2017        PMID： 29066521     DOI： 10.1136/archdischild-2016-311820

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  4 in total

1.  Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.

Authors:  Shuko Joseph; Cunyi Wang; Kate Bushby; Michaela Guglieri; Iain Horrocks; Volker Straub; S Faisal Ahmed; Sze Choong Wong
Journal:  JAMA Neurol       Date:  2019-06-01       Impact factor: 18.302

2.  L'évaluation et l'optimisation de la santé osseuse chez les enfants ayant des affections chroniques.

Authors:  Celia Rodd; Nicole Kirouac; Julia Orkin; Ruth Grimes
Journal:  Paediatr Child Health       Date:  2022-07-18       Impact factor: 2.600

3.  Evaluating and optimizing bone health in children with chronic health conditions.

Authors:  Celia Rodd; Nicole Kirouac; Julia Orkin; Ruth Grimes
Journal:  Paediatr Child Health       Date:  2022-07-18       Impact factor: 2.600

4.  Pathogenic variants in GNPTAB and GNPTG encoding distinct subunits of GlcNAc-1-phosphotransferase differentially impact bone resorption in patients with mucolipidosis type II and III.

Authors:  Giorgia Di Lorenzo; Lena M Westermann; Timur A Yorgan; Julian Stürznickel; Nataniel F Ludwig; Luise S Ammer; Anke Baranowsky; Shiva Ahmadi; Elham Pourbarkhordariesfandabadi; Sandra R Breyer; Tim N Board; Anne Foster; Jean Mercer; Karen Tylee; Renata Voltolini Velho; Michaela Schweizer; Thomas Renné; Thomas Braulke; Dévora N Randon; Fernanda Sperb-Ludwig; Louise Lapagesse de Camargo Pinto; Carolina Araujo Moreno; Denise P Cavalcanti; Michael Amling; Kerstin Kutsche; Dominic Winter; Nicole M Muschol; Ida V D Schwartz; Tim Rolvien; Tatyana Danyukova; Thorsten Schinke; Sandra Pohl
Journal:  Genet Med       Date:  2021-08-02       Impact factor: 8.822
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.